Primmune Therapeutics
PrivateLast Round
Series B
Jan 26, 2026
Total Funding Raised
$93.1M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Primmune Therapeutics is a biotechnology company that develops orally administered toll-like receptor 7 (TLR7) agonists to enhance innate immunity for the treatment of cancer and viral diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Defense Tech
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Primmune Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Primmune Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 26, 2026 | ||||
| Grant | Mar 20, 2024 | ||||
| Series A | Jan 12, 2021 | ||||
| Series A | Oct 27, 2020 | ||||
| Seed | Mar 2, 2020 |
Key People
Founding team and executive leadership
Primmune Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CAM Capital | Series A, Seed |
| BioRock Ventures | Series A, Seed |
| Bioqube Ventures | Series B, Series A |
| Oberland Capital Management | Series B, Series A |
| BioBrit | Series A, Seed |
| Polaris Partners | Series A |
| Samsara BioCapital | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 5, 2026
Chris Krueger appointed as Executive Chairman of the Board.
- Feb 5, 2026
Andrew Sharabi, M.D., Ph.D. appointed as new CMO.
Primmune Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Primmune Therapeutics's valuation, stock price, and market status.